Skip to main content

1 Result(s)

within Paolo Antonio Ascierto Remove this filter Biomedicine Remove this filter Infectious Diseases Remove this filter Metabolic Diseases Remove this filter

and

  1. No Access

    Article

    Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

    Blocking programmed death 1 (PD-1) may enhance the durability of anti-tumor responses that are induced by the combined inhibition of BRAF and MEK1. Here we performed a randomized phase 2 trial ( ...

    Paolo Antonio Ascierto, Pier Francesco Ferrucci, Rosalie Fisher… in Nature Medicine (2019)